# **Original article:**

# Study on Clinical Co relation between Vit D deficiency and depressive disorders

# Dr Malaya Kant Singh\*

MD Psychiatry, Professor Department of Psychiatry,

Career Institute of Medical Sciences and Hospital, Lucknow

Corresponding Author: Dr Malaya Kant Singh, 1/182, Sector 1, Vikas Nagar, Lucknow 226022, UP, India. Ph 0091-9415081144. E mail: malayakant@gmail.com



#### Abstract:

**Background:** High prevalence of depression as well as Vitamin D deficiency in general population, potential impact of Vitamin D deficiency on treatment and outcome of depression, lack of Indian data on this association, and wider acceptability, negligible side effects and cost effective approach with Vitamin D supplementation have given us impetus to study in this area and to fill the research gap with Indian data.

**Aim and Objectives:** The present study aimed to assess Vitamin D status in patients with depression and to see role of Vitamin D supplementation in outcome of depressive disorders.

**Material and Methods:** The study was carried out at the psychiatry outpatient clinic of a tertiary care hospital in Lucknow, North India. Totally 120 patients with depressive disorders were consecutively recruited and assessed for their severity of depression, functionality score, physical and nutrition habits score, obesity (as per Asian criteria body mass index (BMI)  $\geq$ 25) and serum Vitamin D level. They were followed up monthly for 1 year. Out of 120 patients, only 100 patients continued regular follow-ups for 1 year. Therefore, we have used the data of those 100 patients for final analysis.

**Results:** The mean age of onset of depression, duration of depressive disorder, and monthly sun exposure were 32 years, 39 months, and 48 h, respectively. First episode depressive episode was the most common psychiatric disorder (75%), followed by recurrent depressive episode and dysthymia. Nearly one-third of patients were obese (BMI  $\ge$  25) (35%). Mean serum Vitamin D level was 10.95 ng/ml.

**Conclusion:** Majority (80%) of patients with depression had Vitamin D deficiency. It was seen more in unemployed or homemaker, females, patients with smaller height, and from nuclear family. These all factors were also found significant predictors for hypovitaminosis D. Vitamin D deficient patients took significantly longer time in remission than nondeficient patients.

Keywords: Depression, Hypovitaminosis D. Time to remission, Vitamin D.

## **Background:**

Depression is a major public health problem and is projected to be the second most important cause of disability worldwide in 2020.<sup>1</sup> This trend is accompanied by soaring costs for treatment and reduced productivity.<sup>2</sup> Depression aetiology and pathophysiology have not yet been fully elucidated. Recent

advances in basic and clinical research highlighted the potential role of new biological factors that may affect mood in combination with the more traditional neurochemical and neuroendocrine mechanisms.

Furthermore, stigma, poor acceptability of psychiatric treatment, side effects of antidepressants are resulting in poor treatment adherence and high relapse rate of depression. Nutritional deficiency, especially of Vitamin D, is highly prevalent and potentially modifiable.<sup>3</sup> Globally about 1 billion people have Vitamin D deficiency.<sup>4</sup> Vitamin D is involved in numerous brain processes including neuroimmunomodulation, neuroprotection, neuroplasticity, regulation of neurotrophic factors, and making it biologically plausible to be associated with depression.

Several Indian studies have reported high prevalence of Vitamin D deficiency across India, including in healthy, middle-aged health care professionals (79%).<sup>5</sup> High prevalence of depression as well as Vitamin D deficiency in general population, potential impact of Vitamin D deficiency on treatment and outcome of depression, lack of Indian data on this association, and wider acceptability, negligible side effects and cost effective approach with Vitamin D supplementation have given us impetus to study in this area and to fill the research gap with Indian data.

# Aim and Objectives:

The present study was aimed to:

- Assess Vitamin D status in patients with depression.
- Its association with time to remission.
- Role of Vitamin D supplementation in the outcome of patients with depressive disorders.

## Material and Methods:

The study was approved by the Institutional Ethics Review Committee of Career Medical college and Hospital. The study was carried out at the psychiatry outpatient clinic of a tertiary care hospital in Lucknow, North India. The study sample comprised consecutive patients, of either gender aged between 18 and 60 years, with depressive disorders (first episode depression, recurrent depressive disorder, and dysthymia) as per International Classification of Diseases, Tenth Revision (ICD-10)<sup>6</sup> consulted to Psychiatry outpatient clinic from January to June 2018. Diagnostic confirmation was done by Mini International Neuropsychiatric Interview (MINI).<sup>7</sup> All the patients with depressive disorder were approached, excluding patients with bipolar depression, psychotic depression, and any other comorbid psychiatric or chronic physical disorders. Written informed consent was sought from all the patients. The assessment was done at their first visit to psychiatry outpatient clinic.

Totally 120 patients with depressive disorders were consecutively recruited and assessed for their severity of depression, functionality score, physical and nutrition habits score, obesity (as per Asian criteria body mass index (BMI)  $\geq$ 25)<sup>8</sup> and serum Vitamin D level. They were followed up monthly for 1 year. Out of 120 patients, only 100 patients continued regular follow-ups for 1 year. Therefore, we have used the data of those 100 patients for final analysis.

Including demographic and clinical profile sheet following instruments were used:

**Mini International Neuropsychiatric Interview** : The MINI is a clinician based, brief structured interview for diagnosis of a major axis I psychiatric disorders in Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) and ICD-10 and divided into modules corresponding to

diagnostic categories. MINI is compared with Structured Clinical Interview for DSM-III-R-patient version and Composite International Diagnostic Interview for ICD-10 and found to have high validity and reliability.<sup>7</sup>

**Hamilton Depression Rating Scale**: It is a clinician-rated scale, with 17 items and each item is rated from 0 to 4, according to intensity and frequency of symptoms in the past few days.<sup>9</sup>

**Health Promoting Lifestyle Profile-II**: It has been used extensively to explore health promoting lifestyle variables and found to have high construct validity and reliability. It is a 52-item self-report instrument, on likert scale from 1 to 4 with 1 = never, 2 = sometimes, 3 = often, and 4 = routinely. We have used two subscales, that is, physical activity and nutritional habit containing 8 and 9 items, respectively, with total score ranging from 17 to 68.<sup>10</sup>

**Global Assessment of Functioning Scale**: It was developed to rate Axis-V of DSM diagnostic system. It measures overall functional status in relation to psychiatric symptoms.<sup>11</sup>

Vitamin D status was measured by assessing circulating levels of serum 25-hydroxyvitamin D3 (25(OH) D) level, which reflects total Vitamin D from dietary intake and sunlight exposure, and including the conversion of Vitamin D from adipose stores in the liver. Therefore, it is the best indicator of overall Vitamin D status.<sup>12</sup> Fasting blood samples were obtained in the morning from 10 am to 1 pm and kept frozen at 80°C and never thawed before analysis. Serum 25(OH) D was measured using chemiluminescence essay by DiaSorin.

Vitamin D deficiency is defined as a level <20 ng/mL.<sup>13</sup> The number of sunlight hours in the 12 weeks preceding blood drawing was assessed, as a possible factor affecting serum Vitamin D level. As a standard protocol, we have prescribed antidepressants to all the study participants, commonly selective serotonin reuptake inhibitor (SSRI), with escitalopram being most common agent. Patients with hypovitaminosis D were given Vitamin D supplementation as per standard protocol one sachet of cholecalciferol (Vitamin D3) 60,000 units weekly for 8 weeks and later once a month to maintain the level.<sup>14</sup>

## **Results:**

We have analysed the data of 100 patients who continued regular follow-up for 1 year. As depicted in Table 1, mean age was 35 years. More than half of patients were females, unemployed or homemaker, from extended or joint families, and urban locality. The majority of patients were married, and Hindu by religion.

Variable	Mean ± SD (range)	
Age (in years)	35±10.05(18-60)	
Education (in years)	8.7±5.76(0-18)	
Monthly family income	23500±3452(3000-100,000)	
Variable	Frequency %	
Sex		
Male	40 (40%)	
Female	60 (60%)	
Marital status		
Single	15 (15%)	

85 (85%)
45 (45%)
55 (55%)
70 (70%)
30 (30%)
35 (35%)
65 (65%)
57 (57%)
43 (43%)

 Table 1: Socio demographic profile of study population (n=100)

The mean age of onset of depression, duration of depressive disorder, and monthly sun exposure were 32 years, 39 months, and 48 h, respectively. First episode depressive episode was the most common psychiatric disorder (75%), followed by recurrent depressive episode and dysthymia. Mean Hamilton Depression Rating Scale score was 17 with moderate to severe depression in nearly half of the patients [Table 2].Nearly one-third of patients were obese (BMI  $\geq$  25) (35%). Mean serum Vitamin D level was 10.95 ng/ml. The majority of patients were Vitamin D deficient (80%).

Variable	Mean ± SD (range)	
Age at onset of depression (years)	32.6±10.45 (15-60)	
Duration of illness (months)	38.9±48.72 (1-240)	
Monthly sun exposure (hours)	48.05±40.08 (1-176)	
Depression severity score (HDRS)	17.52±6.58 (8-31)	
Serum Vit D levels	10.95±6.5 (4-28)	
Variable	Frequency %	
Diagnosis		
First episode of depression	75 (75%)	
Recurrent depressive disorder	15 (15%)	
Dysthymia	10 (10%)	
Depression severity		
Mild HDRS (10-13)	25 (25%)	
Mild to Moderate HDRS (14-17)	20 (20%)	
Moderate to severe HDRS (>17)	55 (55%)	
Obesity (BMI≥25)	35 (35%)	
Vit D deficiency (<20ng/ml)	80 (80%)	

Table 2: Clinical Profile of patients (n=100)

Patients with hypovitaminosis D had a greater proportion of females, unemployed or homemaker, and were from nuclear family, smaller in height, and took longer time in remission of depression, compared to patients with normal Vitamin D level [Table 3].

Variables	Frequency %	Chi Square p value		
Patient with vitamin				Patient without vit D
	D deficiency (n=80)	deficiency (n=20)		
Gender				
Male	35 (43.75)	05 (25)	4.67 (0.04)	
Female	45 (56.25)	15 (75)		
Occupation				
Employed	34 (42.5)	11 (55)	5.9 (0.010)	
Unemployed	46 (57.5)	09 (45)		
Family				
Nuclear	30 (37.5)	05 (25)	5.56 (0.018)	
Joint	50 (62.5)	15 (75)		
Religion				
Hindu	60 (75)	10 (50)	0.90 (0.22)	
Non Hindu	20 (25)	10 (50)		
Locality				
Urban	42 (52.5)	15 (75)	2.4 (0.08)	
Rural	38 (47.5)	05 (25)		
BMI >25 Kg/mt sq	30 (37.5)	05 (25)	1.25 (0.51)	

Table 3: Comparison of demographic profile of patients for having Vit D deficiency.

Variables	SE	OR	Significance	CI
Gender-female	0.60	3.45	0.041	1.04-12.02
Occupation-	0.62	4.41	0.021	1.23-15.74
unemployed				
Nuclear family	1.05	8.65	0.043	1.06-70.05
Height	0.05	0.88	0.001	0.82-0.95

# Table 4: Important predictors of Hypovitaminosis D.

Predictors of hypovitaminosis D were assessed by using simple binary logistic regression analysis. As shown in Table 4, significant predictors of hypovitaminosis D were female gender, unemployment, nuclear family and smaller height.

Majority of patients with hypovitaminosis D were given Vitamin D supplementation as per standard protocol-one sachet of cholecalciferol (Vitamin D3) 60,000 units weekly for 8 weeks and followed by once a month dose to maintain the level. Their blood sample for Vitamin D estimation was drawn at first visit, but owing to reporting time and monthly follow-up, Vitamin D supplementation was started nearly 1 month after their first contact. Time to remission in patients with Vitamin D deficiency after

supplementation was longer than patients with normal Vitamin D levels, but the difference was statistically not significant (1.95 months [standard deviation (SD) 2.24 months] vs. 1.35 months [SD 0.57 month], Mann– Whitney value = 160.0, P = 0.36).

#### **Discussion**:

Baseline low Vitamin D level is found to be associated with developing depression over the time<sup>7,8</sup> and the same is also supported by several systematic reviews and meta-analysis.<sup>15-17</sup> Meta-analysis of data from more than 50,000 study participants found a significant inverse association between serum 25(OH) D levels and the risk of depression.<sup>17</sup> The odds ratio for having a current depressive episode was 1.8-fold higher in individuals with deficient Vitamin D compared to those with sufficient Vitamin D.<sup>18</sup> A systematic review and meta-analysis of cohort studies by Anglin et al.<sup>15</sup> reported significantly increased risk of developing depression with low Vitamin D levels (hazard ratio = 2.21, P < 0.001). On the other side, depression may also be a risk factor for developing Vitamin D deficiency, as depressed people may consume less nutritious diet, stay indoors, and exercise less; all these health behaviours contribute to hypovitaminosis D.<sup>6</sup>

Given the high prevalence of both Vitamin D deficiency and depression, their association has significant public health implications. Vitamin D supplementation could play a significant role in the treatment of depression, and it has been supported by world literature,<sup>7-8,15-17</sup> but we don't have enough study from India. Index study is an attempt to fill this gap in literature.

Similar to earlier study by Dana-Alamdari et al.,<sup>19</sup> majority of our patients had Vitamin D deficiency (80%). In the present study, hypovitaminosis D was seen more in unemployed or homemakers, female patients, with smaller height, and from nuclear family. To elaborate further, unemployed or homemaker patients and females were less exposed to sun, patients with smaller height were having lesser body surface area, therefore having lesser production of Vitamin D with sun exposure. Patients from nuclear family might have lesser dietary intake of Vitamin D rich food. Other association of Vitamin D status was found with religion, but it might be associated with dietary pattern directly or indirectly. Collin et al.<sup>20</sup> reported lower probability of recurrent depressive symptoms with  $\geq 10$  ng/mL level of 25(OH) D. In index study, we did not find such association on comparing our patients with first episode versus recurrent episode of depression. Grudet et al.<sup>21</sup> found significantly lower Vitamin D level in suicide attempters compared to depressed nonsuicidal patients. We could not find such association of Vitamin D level in our patients with suicidal ideation, as the majority of them had suicidal ideas but very few of them had suicide attempt in past. Milaneschi et al.<sup>22</sup> and Polak et al.<sup>23</sup> reported inverse association of Vitamin D with depression severity. While similar to Dana-Alamdari et al.,<sup>19</sup> index study could not find such association. Milaneschi et al.<sup>22</sup> reported greater risk (1.74 times) of developing depression in Vitamin D deficient patients and greater duration of depressive symptoms, compared to patients with normal Vitamin D levels. Similar to Milaneschi et al.,<sup>22</sup> index study reported longer time to remission in Vitamin D deficient patients.

Augmentation strategies in depression treatment are being used commonly in patients with incomplete remission<sup>24</sup> or the presence of subsyndromal symptoms.<sup>25</sup> Co-administration of nutraceuticals or nutritional agents may also enhance antidepressant effects, either by synergistically augmenting effects of

antidepressants or by other biological effects.<sup>26</sup> Many nutraceuticals are cost effective, safe and evidencebased augmenting agents for depression treatment including Vitamin D supplementation. Similar to earlier evidence,<sup>21</sup> we have found Vitamin D supplementation safe and effective as an adjunctive treatment in depressive disorder with hypovitaminosis D.

### **Conclusion:**

Majority (80%) of patients with depression had Vitamin D deficiency. It was seen more in unemployed or homemaker, females, patients with smaller height, and from nuclear family. These all factors were also found significant predictors for hypovitaminosis D. Vitamin D deficient patients took significantly longer time in remission than nondeficient patients. All the patients with Vitamin D deficiency received supplementation and subsequently their time to remission was comparable to nondeficient group. Therefore it highlights the need for timely assessment and treatment of hypovitaminosis D for effective management of depression to avoid delay in response, treatment resistance, incomplete remission, or residual symptoms.

#### Limitations:

The present study has following limitations: Hospital based sample, smaller sample size for patients with normal Vitamin D status, causal association cannot be determined between Vitamin D levels and depression and due to logistic issues Vitamin D supplementation was started nearly 1 month after their first contact and we could not repeat Vitamin D serum levels after the supplementation. Future studies should be conducted in larger sample from hospital and community, with healthy controls, prospective and multicentric study design, and detailed exploration of physical activity, dietary patterns, sun exposure and other health promoting lifestyle behaviours and future research should attempt to overcome above limitations.

## Acknowledgement:

We are thankful to Dr Abhishek Arun and his team for assistance in medical writing. We are also thankful to staff and resident doctors of department of Psychiatry Career Institute of Medical sciences and Hospital. Above all we are thankful to all those who participated in this study.

#### **References:**

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990 2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504.

- 2. Cuijpers P, Beekman AT, Reynolds CF., III. Preventing depression: a global priority. JAMA 2012; 307: 1033–1034.
- 3. Yetley EA. Assessing the Vitamin D status of the US population. Am J Clin Nutr 2008;88:558S-64S.

4. Hoang MT, Defina LF, Willis BL, Leonard DS, Weiner MF, Brown ES. Association between low serum 25hydroxyvitamin D and depression in a large sample of healthy adults: The Cooper Center Longitudinal Study. Mayo Clin Proc 2011;86:1050-5.

5. Beloyartseva M, Mithal A, Kaur P, Kalra S, Baruah MP, Mukhopadhyay S, et al. Widespread Vitamin D deficiency among Indian health care professionals. Arch Osteoporos 2012;7:187-92.

6. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders – Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO; 1992.

7. Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. The Mini international neuropsychiatric interview (M.I.N.I.) a short diagnostic structured interview: Reliability and validity according to the CIDI. Eur Psychiatry 1997;12:224-31.

8. Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009;57:163-70.

9. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.

10. Walker SN, Sechrist KR, Pender NJ. The health-promoting lifestyle profile: Development and psychometric characteristics. Nurs Res 1987;36:76-81.

11. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-71.

12. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011;364:248-54.

13. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.

14. Goswami R, Gupta N, Ray D, Singh N, Tomar N. Pattern of 25-hydroxy Vitamin D response at short (2 month) and long (1 year) interval after 8 weeks of oral supplementation with cholecalciferol in Asian Indians with chronic hypovitaminosis D. Br J Nutr 2008;100:526-9.

15. Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: Systematic review and meta-analysis. Br J Psychiatry 2013;202:100-7.

16. Spedding S. Vitamin D and depression: A systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients 2014;6:1501-18.

17. Ju SY, Lee YJ, Jeong SN. Serum 25-hydroxyvitamin D levels and the risk of depression: A systematic review and meta-analysis. J Nutr Health Aging 2013;17:447-55.

18. Ganji V, Milone C, Cody MM, McCarty F, Wang YT. Serum Vitamin D concentrations are related to depression in young adult US population: The Third National Health and Nutrition Examination Survey. Int Arch Med 2010;3:29.

19. Dana-Alamdari L, Kheirouri S, Noorazar SG. Serum 25-hydroxyvitamin D in patients with major depressive disorder. Iran J Public Health 2015;44:690-7.

20. Collin C, Assmann KE, Deschasaux M, Andreeva VA, Lemogne C, Charnaux N, et al. Plasma Vitamin D status and recurrent depressive symptoms in the French SU.VI.MAX cohort. Eur J Nutr 2016. doi:10.1007/s00394-016-1269-y.

21. Grudet C, Malm J, Westrin A, Brundin L. Suicidal patients are deficient in Vitamin D, associated with a proinflammatory status in the blood. Psychoneuroendocrinology 2014;50:210-9.

22. Milaneschi Y, Hoogendijk W, Lips P, Heijboer AC, Schoevers R, van Hemert AM, et al. The association between low Vitamin D and depressive disorders. Mol Psychiatry 2014;19:444-51.

23. Polak MA, Houghton LA, Reeder AI, Harper MJ, Conner TS. Serum 25-hydroxyvitamin D concentrations and depressive symptoms among young adult men and women. Nutrients 2014;6:4720-30.

24. Shelton RC. What are the comparative benefits and harms of augmentation treatments in major depression? J Clin Psychiatry 2015;76:e531-3.

25. Pietrzak RH, Kinley J, Afifi TO, Enns MW, Fawcett J, Sareen J. Subsyndromal depression in the United States: Prevalence, course, and risk for incident psychiatric outcomes. Psychol Med 2013;43:1401-14.

26. Sarris J, Stough C, Bousman C, Murphy J, Savage K, Smith DJ, et al. An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. Adv Integr Med 2015;2:49-55.

------

Date of Submission: 01 January2020 Date of Peer Review: 03 February 2020 Date of Acceptance: 27 February 2020 Date of Publishing: 12 March 2020 Author Declaration: Source of support: Nil , Conflict of interest: Nil Ethics Committee Approval obtained for this study? Yes Was informed consent obtained from the subjects involved in the study? Yes For any images presented appropriate consent has been obtained from the subjects: NA Plagiarism Checked: Urkund Software Author work published under a Creative Commons Attribution 4.0 International License



CC BY 4.0

DOI: 10.36848/IJBAMR/2020/12165.51220